Shang-Gin Wu

Pulmonary and Respiratory Medicine · 2018

A researcher in the Science corpus: 1 paper; trusts 7 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Shang-Gin Wu trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. L. Sequist
  2. C. Yun
  3. M. Kris
  4. P. Jänne
  5. William Pao
  6. Gregory Riely
  7. Jie Yang
  8. Kristen E. Mengwasser
  9. T. Boggon
  10. J. Engelman

Papers from Shang-Gin Wu's perspective

Ordered by how strongly the researchers Shang-Gin Wu trusts endorse each paper. Same corpus, a different order for every researcher.

  1. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  2. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer (Cancer Discovery)
  3. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (Nature)
  4. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (Proceedings of the National Academy of Sciences of the United States of America)
  5. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity (Clinical Cancer Research)
  6. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (Journal of the American Medical Association (JAMA))
  7. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (Proceedings of the National Academy of Sciences of the United States of America)
  8. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (Journal of Clinical Oncology)
  9. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (Proceedings of the National Academy of Sciences of the United States of America)
  10. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (Journal of Clinical Oncology)

Their papers